Pacira BioSciences Inc.
PCRX | NASDAQ
$24.78
+$0.67 (+2.78%)
Sep 22, 2026, 2:02 PM ET · Market open
Company Profile
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Key Executives
| Name | Position |
|---|---|
| Frank D. Lee | Chief Executive Officer & Director |
| Shawn Cross | Chief Financial Officer |
| Anthony Molloy | Chief Legal & Compliance Officer |
| Brendan Teehan | Chief Commercial Officer |
| Christopher C. Young | Chief Manufacturing Officer |
| Jonathan Slonin | Chief Medical Officer |
| Kristen Williams | Chief Administrative Officer & Secretary |
| Krys Corbett | Chief Business Officer |
| Lauren Bullaro Riker | Principal Accounting Officer & Senior Vice President of Finance |
| Susan Mesco | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 04, 2026 | S-8 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
Pacira BioSciences Inc.
| Country | United States |
| IPO Date | Feb 2, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 827 |
| CEO | Frank D. Lee |
Contact Details
2000 Sierra Point Parkway Brisbane,
California 94005 United States
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| SIC Code | 2834 |
Recent News
- 2 months ago / zacks.comPacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
- 2 months ago / seekingalpha.comPacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comPacira (PCRX) Tops Q2 Earnings and Revenue Estimates
- 2 months ago / globenewswire.comPacira BioSciences Reports Second Quarter 2026 Financial Results
- 2 months ago / globenewswire.comPacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
- 2 months ago / globenewswire.comPacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
- 5 months ago / globenewswire.comPharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
- 5 months ago / zacks.comPacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
- 5 months ago / seekingalpha.comPacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
- 5 months ago / zacks.comPacira (PCRX) Q1 Earnings Miss Estimates
Add to Watchlist
Select watchlists to add or remove PCRX